Testing the HemoCept device during heart valve replacement for aortic valve stenosis
Checks whether the HemoCept device detects blood volume and heart efficiency changes in valve surgery.
Key facts
- Who runs it
- HemoCept Inc.
- Where
- Boulder, United StatesSee the site
- Trial code
- Registry title
- Detecting Changes in Arterial Blood Volume and Cardiac Efficiency
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 29 Apr 2025
- Planned end
- Sept 2026
- Type of study
- Observational
- Record updated
- 13 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who need a trans-aortic valve replacement (TAVR) for aortic valve narrowing. It tests whether the HemoCept device can detect changes in blood volume and heart efficiency.
- Age
- 18 to 80 years, including 18 and 80.
- Sex
- All sexes can join.
- Disease stage
- Aortic valve stenosis (narrowing of the aortic valve) that needs a trans-aortic valve replacement.
Main reasons for not taking part
- Being pregnant, breast-feeding, or planning to become pregnant during the study.
- A history of Long Q-T syndrome (a heart rhythm problem).
- A history of cardiac channelopathies (inherited heart electrical problems).
- A history of seizures.
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Subjects or representatives must have voluntarily signed the informed consent form before any study related procedures
- Subjects can be any gender but must be between (and including) the ages of 18 and 80
- Subject ls being treated by the participating healthcare facility ; ., Subject requires a trans-aortic valve replacement
- Subject is able and willing to provide informed consent and HIPM authorization
- Subject is able and willing to meet all study requirements
Who cannot take part
- Subject has a personal medical history that includes:; Long O-T syndrome; Cardiac channelopathies; Seizures
- Subject is pregnant, breast-feeding, or intends to become pregnant during the course of the study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in United States
- Boulder HeartBoulder, United StatesContact: Katharine AdkinsTaking people
About the trial
What the trial wants to find out
The objective of this Pilot Study is to demonstrate the efficacy of the Hemocept device in detecting changes in arterial blood volume and cardiac efficiency.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Pilot Clinical Study to Assess Correlation Between Arterial Blood Volume Status and Cardiac Efficiency, and HemoCept Device Data in Trans-Aortic Valve Replacement (TAVR} Surgery
- Plain-language title
- Testing the HemoCept device during heart valve replacement for aortic valve stenosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07205341, who can take part
- Record updated
- 13 April 2026